China can not position itself as a Mecca for clinical trials due to its ongoing lack of transparency , an inability to protect patients and inadequate infrastructure , writes Anne ##son , a senior scientist at Boston 's Halloran Consulting Group . She said the country has - on the strength of it - made an effort to align its industry with the Good Clinical Practice guidelines and pledged to implement International guidelines on Harmonization recommendations . However , she argues that in reality , few concrete steps have been taken , with ongoing issues involving clinical trial investigators tasked with interpreting the guidelines .
China cannot position itself as a Mecca for clinical trials due to its ongoing lack of transparency, an inability to protect patients and inadequate infrastructure, writes Anne Poli, a senior consultant at Boston's Halloran Consulting Group. She said the country has - on the face of it - made an effort to align its industry with the Good Clinical Practice guidelines and pledged to implement International Conference on Harmonization recommendations. However, Poli warned that in reality, few concrete steps have been taken, with ongoing issues including clinical trial investigators tasked with interpreting the guidelines.